{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:29:52Z","timestamp":1786116592419,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54693-9","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T07:05:56Z","timestamp":1779865556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["One year follow-up of physical activity and health-related quality of life in youth with Cystic Fibrosis in the modulator era"],"prefix":"10.1038","volume":"16","author":[{"given":"Manon","family":"Kinaupenne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Vandekerckhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Van Biervliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Schaballie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristof","family":"Vandekerckhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen","family":"Demeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"De Craemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"10290","key":"54693_CR1","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","volume":"397","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg, M., Haq, I. J., Polineni, D. & Davies, J. C. Cystic fibrosis. Lancet 397 (10290), 2195\u20132211 (2021).","journal-title":"Lancet"},{"issue":"10212","key":"54693_CR2","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman, H. G. M. et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394 (10212), 1940\u20131948 (2019).","journal-title":"Lancet"},{"issue":"3","key":"54693_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","volume":"10","author":"S Sutharsan","year":"2022","unstructured":"Sutharsan, S. et al. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med. 10 (3), 267\u2013277 (2022).","journal-title":"Lancet Respir Med."},{"issue":"19","key":"54693_CR4","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton, P. G. et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl. J. Med. 381 (19), 1809\u20131819 (2019).","journal-title":"N Engl. J. Med."},{"key":"54693_CR5","doi-asserted-by":"publisher","first-page":"107749","DOI":"10.1016\/j.rmed.2024.107749","volume":"232","author":"M Kinaupenne","year":"2024","unstructured":"Kinaupenne, M. et al. Lower physical activity levels in youth with Cystic Fibrosis compared to healthy controls: A multicentre comparative study. Respir Med. 232, 107749 (2024).","journal-title":"Respir Med."},{"issue":"165","key":"54693_CR6","doi-asserted-by":"publisher","first-page":"220010","DOI":"10.1183\/16000617.0010-2022","volume":"31","author":"M Kinaupenne","year":"2022","unstructured":"Kinaupenne, M. et al. Physical activity and its correlates in people with cystic fibrosis: a systematic review. Eur. Respiratory Rev. 31 (165), 220010 (2022).","journal-title":"Eur. Respiratory Rev."},{"issue":"5","key":"54693_CR7","first-page":"123","volume":"24","author":"A Barrero","year":"2024","unstructured":"Barrero, A. et al. Physical activity levels in cystic fibrosis patients before and after triple modulator therapy: A single-center retrospective pilot study. J. Phys. Educ. Sport. 24 (5), 123 (2024).","journal-title":"J. Phys. Educ. Sport"},{"issue":"11","key":"54693_CR8","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/ppul.26078","volume":"57","author":"AJ Causer","year":"2022","unstructured":"Causer, A. J. et al. Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis. Pediatr. Pulmonol. 57 (11), 2652\u20132658 (2022).","journal-title":"Pediatr. Pulmonol."},{"key":"54693_CR9","doi-asserted-by":"publisher","first-page":"1284878","DOI":"10.3389\/fspor.2024.1284878","volume":"6","author":"W Gruber","year":"2024","unstructured":"Gruber, W. et al. Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor\/tezacaftor\/ivacaftor. Front. Sports Act. Living. 6, 1284878 (2024).","journal-title":"Front. Sports Act. Living"},{"issue":"2","key":"54693_CR10","first-page":"126","volume":"100","author":"CJ Caspersen","year":"1985","unstructured":"Caspersen, C. J., Powell, K. E. & Christenson, G. M. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public. Health Rep. 100 (2), 126\u2013131 (1985).","journal-title":"Public. Health Rep."},{"key":"54693_CR11","doi-asserted-by":"crossref","unstructured":"Kinaupenne, M. et al. Influencing factors of physical activity in youth with Cystic Fibrosis: a socio-ecological approach. ERJ Open. Res. :00704\u20132025. (2025).","DOI":"10.1183\/23120541.00704-2025"},{"issue":"10","key":"54693_CR12","doi-asserted-by":"publisher","first-page":"6114","DOI":"10.3390\/ijerph19106114","volume":"19","author":"SA Aspinall","year":"2022","unstructured":"Aspinall, S. A., Mackintosh, K. A., Hill, D. M., Cope, B. & McNarry, M. A. Evaluating the effect of kaftrio on perspectives of health and wellbeing in individuals with cystic fibrosis. Int. J. Environ. Res. Public. Health. 19 (10), 6114 (2022).","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"54693_CR13","doi-asserted-by":"crossref","unstructured":"Quittner, A. L. Measurement of quality of life in cystic fibrosis. Curr. Opin. Pulm Med. ;4(6). (1998).","DOI":"10.1097\/00063198-199811000-00003"},{"issue":"4","key":"54693_CR14","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1378\/chest.128.4.2347","volume":"128","author":"AL Quittner","year":"2005","unstructured":"Quittner, A. L., Buu, A., Messer, M. A., Modi, A. C. & Watrous, M. Development and Validation of the Cystic Fibrosis Questionnaire in the United States: A Health-Related Quality-of-Life Measure for Cystic Fibrosis. Chest 128 (4), 2347\u20132354 (2005).","journal-title":"Chest"},{"issue":"1","key":"54693_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s41687-025-00879-0","volume":"9","author":"B Francesca","year":"2025","unstructured":"Francesca, B. et al. Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor\/Tezacaftor\/Ivacaftor treatment. J. Patient Rep. Outcomes. 9 (1), 48 (2025).","journal-title":"J. Patient Rep. Outcomes"},{"issue":"1","key":"54693_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jcf.2022.08.018","volume":"22","author":"I Fajac","year":"2023","unstructured":"Fajac, I. et al. Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor. J. Cyst. Fibros. 22 (1), 119\u2013123 (2023).","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"54693_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/alr.22700","volume":"11","author":"E DiMango","year":"2021","unstructured":"DiMango, E. et al. Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis. Int. Forum Allergy Rhinol. 11 (1), 75\u201378 (2021).","journal-title":"Int. Forum Allergy Rhinol"},{"key":"54693_CR18","doi-asserted-by":"crossref","unstructured":"Gruber, W. et al. Long-Term Follow-Up of Health-Related Quality of Life and Short-Term Intervention with CFTR Modulator Therapy in Adults with Cystic Fibrosis: Evaluation of Changes over Several Years with or without 33 Weeks of CFTR Modulator Therapy. Healthcare (Basel). ;11(21). (2023).","DOI":"10.3390\/healthcare11212873"},{"issue":"6","key":"54693_CR19","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3109\/03014460903049074","volume":"36","author":"M Roelants","year":"2009","unstructured":"Roelants, M., Hauspie, R. & Hoppenbrouwers, K. References for growth and pubertal development from birth to 21 years in Flanders. Belgium Annals Hum. biology. 36 (6), 680\u2013694 (2009).","journal-title":"Belgium Annals Hum. biology"},{"issue":"6","key":"54693_CR20","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","volume":"40","author":"PH Quanjer","year":"2012","unstructured":"Quanjer, P. H. et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur. Respir J. 40 (6), 1324\u20131343 (2012).","journal-title":"Eur. Respir J."},{"issue":"3","key":"54693_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1123\/jmpb.2018-0063","volume":"2","author":"JH Migueles","year":"2019","unstructured":"Migueles, J. H., Rowlands, A. V., Huber, F., Sabia, S. & van Hees, V. T. GGIR: A Research Community\u2013Driven Open Source R Package for Generating Physical Activity and Sleep Outcomes From Multi-Day Raw Accelerometer Data. J. Meas. Phys. Behav. 2 (3), 188\u2013196 (2019).","journal-title":"J. Meas. Phys. Behav."},{"issue":"9","key":"54693_CR22","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s40279-017-0716-0","volume":"47","author":"JH Migueles","year":"2017","unstructured":"Migueles, J. H. et al. Accelerometer Data Collection and Processing Criteria to Assess Physical Activity and Other Outcomes: A Systematic Review and Practical Considerations. Sports Med. 47 (9), 1821\u20131845 (2017).","journal-title":"Sports Med."},{"issue":"9","key":"54693_CR23","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1249\/MSS.0000000000000289","volume":"46","author":"M Hildebrand","year":"2014","unstructured":"Hildebrand, M., VT, V. A. N. H., Hansen, B. H. & Ekelund, U. Age group comparability of raw accelerometer output from wrist- and hip-worn monitors. Med. Sci. Sports Exerc. 46 (9), 1816\u20131824 (2014).","journal-title":"Med. Sci. Sports Exerc."},{"issue":"12","key":"54693_CR24","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1111\/sms.12795","volume":"27","author":"M Hildebrand","year":"2017","unstructured":"Hildebrand, M., Hansen, B. H., van Hees, V. T. & Ekelund, U. Evaluation of raw acceleration sedentary thresholds in children and adults. Scand. J. Med. Sci. Sports. 27 (12), 1814\u20131823 (2017).","journal-title":"Scand. J. Med. Sci. Sports"},{"issue":"1","key":"54693_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jcf.2003.12.006","volume":"3","author":"PH Klijn","year":"2004","unstructured":"Klijn, P. H. et al. Validation of the Dutch cystic fibrosis questionnaire (CFQ) in adolescents and adults. J. Cyst. Fibros. 3 (1), 29\u201336 (2004).","journal-title":"J. Cyst. Fibros."},{"key":"54693_CR26","unstructured":"Mucovereniging Onderhandelingen zijn mislukt. Geen toegang tot het geneesmiddel Kaftrio voor mensen met muco met een zeldzame mutatie.; (2025)."},{"issue":"1","key":"54693_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","volume":"23","author":"KW Southern","year":"2024","unstructured":"Southern, K. W. et al. Standards for the care of people with cystic fibrosis; establishing and maintaining health. J. Cyst. Fibros. 23 (1), 12\u201328 (2024).","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"54693_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1748-5908-6-42","volume":"6","author":"S Michie","year":"2011","unstructured":"Michie, S., van Stralen, M. M. & West, R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. Implement. Sci. 6 (1), 42 (2011).","journal-title":"Implement. Sci."},{"key":"54693_CR29","doi-asserted-by":"crossref","unstructured":"Almulhem, M. et al. Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals. BMJ Open. Respiratory Res. ;9(1). (2022).","DOI":"10.1136\/bmjresp-2022-001420"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54693-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54693-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54693-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:02:34Z","timestamp":1786014154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54693-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54693"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54693-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki. The study was included in the approval of the Ethical Review Committee of Ghent University, Belgium, in line with national regulations (the Ethical Committee of Ghent University Hospital Belgium, BC-10536). Informed consent was provided, explained and signed by all participants and\/or their legal guardians prior to the start of the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24214"}}